Europe — EMA

Oprymea (Pramipexole Dihydrochloride Monohydrate)

Pramipexole, the active ingredient in Oprymea, is a dopamine agonist presented as a (strength/form) for oral use. It treats Parkinson's disease and related movement disorders in adults.

Pramipexole Dihydrochloride Monohydrate

Request sourcing

Pack/s

What is Pramipexole Dihydrochloride Monohydrate?

Pramipexole, the active ingredient in Oprymea, is a dopamine agonist presented as a (strength/form) for oral use. It treats Parkinson's disease and related movement disorders in adults.

GNH USA supplies Oprymea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Pramipexole Dihydrochloride Monohydrate used for?

Pramipexole is a dopamine agonist used in the management of movement‑related disorders. - Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Restless legs syndrome (RLS): reduces the urge to move the legs at night and improves sleep quality. - Secondary dyskinesia: helps to manage drug‑induced movement disorders in Parkinson's patients. - t

What are the side effects of Pramipexole Dihydrochloride Monohydrate?

The

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →